
Amgen (NASDAQ:AMGN) and Kyowa Kirin (OTCPK:KYKOF) announced on Tuesday that their antibody therapy rocatinlimab is safe and effective in the long term, based on data from a Phase 3 trial for patients with atopic dermatitis, a skin condition also
Amgen (NASDAQ:AMGN) and Kyowa Kirin (OTCPK:KYKOF) announced on Tuesday that their antibody therapy rocatinlimab is safe and effective in the long term, based on data from a Phase 3 trial for patients with atopic dermatitis, a skin condition also
© FBT Company 2025. All rights are reserved